These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 24363214)

  • 1. Next generation nanomedicine in the genesis of "Ankaferd blood stopper nanohemostat": a novel chimeric topical hemostatic agent for clinical hemorrhages.
    Beyazit Y; Huri E; Purnak T; Guler MO; Haznedaroglu IC
    Clin Appl Thromb Hemost; 2014 May; 20(4):456-7. PubMed ID: 24363214
    [No Abstract]   [Full Text] [Related]  

  • 2. Effects of Ankaferd Blood Stopper and Celox on the tissue factor activities of warfarin-treated rats.
    Aktop S; Emekli-Alturfan E; Ozer C; Gonul O; Garip H; Yarat A; Goker K
    Clin Appl Thromb Hemost; 2014 Jan; 20(1):16-21. PubMed ID: 23702635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Ankaferd Blood Stopper on Skin Superoxide Dismutase and Catalase Activities in Warfarin-Treated Rats.
    Aktop S; Emekli-Alturfan E; Gönül O; Göçmen G; Garip H; Yarat A; Göker K
    Clin Appl Thromb Hemost; 2017 Mar; 23(2):168-174. PubMed ID: 26354714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ultrastructural analyses of the novel chimeric hemostatic agent generated via nanotechnology, ABS nanohemostat, at the renal tissue level.
    Huri E; Dogantekin E; Hayran M; Malkan UY; Ergun M; Firat A; Beyazit Y; Ustun H; Kekilli M; Dadali M; Astarci M; Haznedaroglu IC
    Springerplus; 2016; 5(1):1931. PubMed ID: 27917335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Generation of Chimeric "ABS Nanohemostat" Complex and Comparing Its Histomorphological In Vivo Effects to the Traditional Ankaferd Hemostat in Controlled Experimental Partial Nephrectomy Model.
    Huri E; Beyazit Y; Mammadov R; Toksoz S; Tekinay AB; Guler MO; Ustun H; Kekilli M; Dadali M; Celik T; Astarci M; Haznedaroglu IC
    Int J Biomater; 2013; 2013():949460. PubMed ID: 23509463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of Ankaferd Blood Stopper as a hemostatic agent: a clinical experience.
    Baykul T; Alanoglu EG; Kocer G
    J Contemp Dent Pract; 2010 Jan; 11(1):E088-94. PubMed ID: 20098971
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ultrastructural and morphological analyses of the in vitro and in vivo hemostatic effects of Ankaferd Blood Stopper.
    Haznedaroglu BZ; Haznedaroglu IC; Walker SL; Bilgili H; Goker H; Kosar A; Aktas A; Captug O; Kurt M; Ozdemir O; Kirazli S; Firat HC
    Clin Appl Thromb Hemost; 2010 Aug; 16(4):446-53. PubMed ID: 19833624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Effect of Ankaferd Blood Stopper? on Epidural Fibrosis After Laminectomy in Rats: An Experimental Study.
    Yilmaz M; Gulabi D; Guclu B; Kaya I; Basak K; Bas A
    Turk Neurosurg; 2017; 27(1):114-118. PubMed ID: 27593739
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pleiotropic cellular, hemostatic, and biological actions of Ankaferd hemostat.
    Haznedaroglu BZ; Beyazit Y; Walker SL; Haznedaroglu IC
    Crit Rev Oncol Hematol; 2012 Jul; 83(1):21-34. PubMed ID: 22079213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New coagulant agent (ankaferd blood stopper) for open hemorrhages in hemophilia with inhibitor.
    Öner AF; Doğan M; Kaya A; Sal E; Bektaş MS; Yesilmen O; Ayhan H; Acikgoz M
    Clin Appl Thromb Hemost; 2010 Dec; 16(6):705-7. PubMed ID: 19528064
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The antioxidant and antimutagenic activities of Ankaferd blood stopper,a natural hemostatic agent used in dentistry.
    Uğur A; Saraç N; Çankal DA; Özle M
    Turk J Med Sci; 2016 Apr; 46(3):657-63. PubMed ID: 27513238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Topical Ankaferd hemostat application for the management of oral cavity bleedings in children with hemorrhagic diathesis.
    Leblebisatan G; Bay A; Karakus SC; Kekilli M; Haznedaroglu IC
    Blood Coagul Fibrinolysis; 2012 Sep; 23(6):494-7. PubMed ID: 22576286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reversible protease-activated receptor 1 downregulation mediated by Ankaferd blood stopper inducible with lipopolysaccharides inside the human umbilical vein endothelial cells.
    Karabiyik A; Güleç S; Yilmaz E; Haznedaroglu I; Akar N
    Clin Appl Thromb Hemost; 2011; 17(6):E165-70. PubMed ID: 21406410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hemostatic efficacy of a traditional medicinal plant extract (Ankaferd Blood Stopper) in bleeding control.
    Sogut O; Erdogan MO; Kose R; Boleken ME; Kaya H; Gokdemir MT; Ozgonul A; Iynen I; Albayrak L; Dokuzoglu MA
    Clin Appl Thromb Hemost; 2015 May; 21(4):348-53. PubMed ID: 24057394
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of a novel haemostatic agent: ankaferd blood stopper in conjunctival incisions.
    Alpay A; Ugurbas SC; Evren C; Bektas S; Calıskan S; Ugurbas SH
    Clin Exp Ophthalmol; 2011 Nov; 39(8):793-8. PubMed ID: 21631678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new hemostatic agent--Ankaferd blood stopper: management of gastrointestinal bleeding in an infant and other experiences in children.
    Yarali N; Oruc M; Bay A; Dalgic B; Bozkaya IO; Arıkoglu T; Kara A; Tunc B
    Pediatr Hematol Oncol; 2010 Nov; 27(8):592-6. PubMed ID: 20863156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of ankaferd blood stopper and microporous polysaccharide hemospheres on epidural fibrosis in rat laminectomy model.
    Özay R; Yavuz OY; Türkoğlu ME; Aktaş A; Yiğit F; Özdemir HM; Şekerci Z
    Acta Cir Bras; 2015 Dec; 30(12):799-805. PubMed ID: 26735050
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy of Ankaferd Blood Stopper in antithrombotic drug-induced primary and secondary hemostatic abnormalities of a rat-bleeding model.
    Kosar A; Cipil HS; Kaya A; Uz B; Haznedaroglu IC; Goker H; Ozdemir O; Ercetin S; Kirazli S; Firat HC
    Blood Coagul Fibrinolysis; 2009 Apr; 20(3):185-90. PubMed ID: 19657315
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ankaferd Blood Stopper as an effective adjunctive hemostatic agent for the management of life-threatening arterial bleeding of the digestive tract.
    Kurt M; Kacar S; Onal IK; Akdogan M; Haznedaroglu IC
    Endoscopy; 2008 Sep; 40 Suppl 2():E262. PubMed ID: 19090459
    [No Abstract]   [Full Text] [Related]  

  • 20. Proteomic and transcriptomic analyses to explain the pleiotropic effects of Ankaferd blood stopper.
    Simsek C; Selek S; Koca M; Haznedaroglu IC
    SAGE Open Med; 2017; 5():2050312117722569. PubMed ID: 28839937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.